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Abstract
Overdiagnosis occurs in a population when conditions are diagnosed correctly 
but the diagnosis produces an unfavourable balance between benefits and 
harms. In cancer screening, overdiagnosed cancers are those that did not 
need to be found because they would not have produced symptoms or led to 
premature death. These overdiagnosed cancers can be distinguished from false 
positives, which occur when an initial screening test suggests that a person is 
at high risk but follow-up testing shows them to be at normal risk. The cancers 
most likely to be overdiagnosed through screening are those of the prostate, 
thyroid, breast and lung. Overdiagnosis in cancer screening arises largely from 
the paradoxical problem that screening is most likely to find the slow-growing 
or dormant cancers that are least likely to harm us, and less likely to find the 
aggressive, fast-growing cancers that cause cancer mortality. This central 
paradox has become clearer over recent decades. The more overdiagnosis is 
produced by a screening program, the less likely the program is to serve its 
ultimate goal of reducing illness and premature death from cancer. Thus, it is 
vital that health professionals and researchers continue an open, scientific inquiry 
into the extent and consequences of overdiagnosis, and devise appropriate 
responses to it.
Introduction 
A cancer screening program tests a large population of healthy people in a 
defined age group, ideally using a simple, affordable test. This test, much like 
a sieve, ‘catches’ those people who are apparently at higher cancer risk and 
directs them to further testing. If diagnostic testing confirms the presence of 
cancer precursors or cancer, preventive or curative treatment is provided. This 
should mean easier, more effective treatment and fewer people progressing 
to late-stage, advanced cancer. The ultimate goal is to reduce the suffering 
and death caused by that cancer in that population without introducing any 
significant additional harms. These are good goals, and some screening 
programs deliver on them (e.g. cervical screening programs1). 
This article explains the problem of overdiagnosis in cancer screening. 
Because overdiagnosis produces harm, a discussion of overdiagnosis may be 
perceived to be a general condemnation of cancer screening. We do not intend 
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Key points 
• An overdiagnosed cancer is correctly 
diagnosed but would not have produced 
symptoms or premature death if left 
undetected; treating these cancers results 
in harm instead of benefit
• Cancer screening is one driver of 
cancer overdiagnosis 
• Overdiagnosis and false positives are 
not equivalent
• Much cancer overdiagnosis occurs 
because cancer is heterogeneous, and 
screening is more likely to detect cancers 
that are least likely to cause cancer death
• We should be concerned about 
overdiagnosis because it harms healthy 
people, creates opportunity costs by 
misdirecting healthcare resources, and 
potentially undermines the ultimate goal of 
screening, which is to reduce suffering and 
premature death
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this, and point to other papers in this issue that focus on 
some of the benefits screening may offer. 
Overdiagnosis is an important concern because it 
potentially breaks the all-important link between screening 
programs and their ultimate goal. The more overdiagnosis 
a screening program produces, the more screening is likely 
to increase rather than decrease suffering and even death 
in populations. Most cancer authorities now acknowledge 
that overdiagnosis is a consideration in screening, including 
in their communication to consumers (e.g. Cancer 
Research UK2, US Preventive Services Task Force3). 
However, significant expert disagreement exists over the 
extent of overdiagnosis1, and screening programs with 
different characteristics are likely to produce overdiagnosis 
to different degrees.4 In this article, we consider what 
overdiagnosis is, why it occurs, what forms of screening it 
is most relevant to, and how we should respond to it.
Overdiagnosis is not a false positive
A common misunderstanding is to conflate overdiagnosis 
and false positives in screening. A false positive occurs 
when the ‘sieve’ of screening ‘catches’ a person who is 
at normal risk of cancer and incorrectly suggests that 
they may be at high risk. After a sometimes anxious wait 
for further testing5, the person is shown to be at normal 
risk. The extent of false positives (and false negatives) 
in a screening program is partly determined by test 
characteristics (a good test produces fewer false results) 
and partly by agreed standards within the program (e.g. the 
agreed cut-off value for a biomarker). 
Defining overdiagnosis 
A false positive occurs when a person is incorrectly told 
that they may have cancer. Cancer overdiagnosis, in 
contrast, occurs when cancers are correctly diagnosed but 
those cancers would not have produced symptoms or been 
identified clinically.6,7 It is very difficult to determine whether 
a particular individual has been overdiagnosed8, particularly 
in cancer screening, because once a person has been 
diagnosed with cancer and treated, no-one can know what 
would have happened without that treatment. 
Cancer overdiagnosis can therefore only be measured 
or statistically estimated in populations.8 Typically, a 
screening program that produces overdiagnosis in a 
population will greatly increase the incidence of early-stage 
cancer or pre-cancer, without reducing the incidence 
of late-stage cancer or mortality from that cancer. This 
is illustrated in Figure 1, using the example of thyroid 
cancer.7,9,10 
The paradox of screening for 
cancer(s)
An important dual paradox drives the overdiagnosis 
problem, one that has become more evident over time. 
First, cancer is complex and heterogeneous.12,13 Second, 
screening programs are more likely to detect slow-growing, 
less aggressive cancers and less likely to detect fast-
growing, more aggressive cancers. This is simply a function 
of time. Screening occurs at regular intervals (e.g. 2, 3 or 
Figure 1. Age-standardised thyroid cancer incidence and mortality rates per 100 000 males/females in Australia, 
1968 to 2013 
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5 years) calculated to provide the best cost:benefit ratio 
and least harm. A slow-growing cancer is asymptomatically 
present in the body for much longer, so is more likely to be 
present at a screening point. In contrast, a fast-growing, 
more aggressive cancer produces symptoms, so is likely 
to prompt the person to see a doctor and be clinically 
diagnosed in the gap between scheduled screenings.14 
These ‘interval cancers’ are not a sign that the screening 
program has failed – they simply demonstrate that a small 
proportion of cancer is extremely aggressive (more so 
than any reasonable screening schedule could catch). This 
relationship is shown in Figure 2. 
Slow-growing, less aggressive cancers are an important 
source of overdiagnosis in screening programs, as they 
may not progress, or may even regress15, and so do 
not need to be found. To quote Otis Brawley, the Chief 
Medical Officer of the American Cancer Society, they are 
“tumours that appear cancerous under the microscope 
but are behaviourally of no clinical threat”.13 These cancers 
bias the perceived outcome of screening in a potentially 
confusing way.16 It is common to see claims such as the 
following: “95% of women whose breast cancer is detected 
by screening are still alive after 5 years, versus only 25% 
of women whose cancer is diagnosed clinically”. This 
may be so, but it is at least partly a function of cancer 
heterogeneity, rather than a benefit of screening. Women 
with slow-growing (screen-detected) cancers are likely to 
survive for 5 years with or without screening. In contrast, 
women with aggressive (clinical, symptomatic) cancers 
are, sadly, less likely to survive 5 years because the 
cancer is aggressive (and thus less likely to be detected 
by screening). Five-year survival will therefore always be 
higher in screen-detected cohorts than in clinically detected 
cohorts. This does not, however, prove that screening 
reduces suffering or premature cancer death. 
A valid measure of the benefit of screening is the 
difference in absolute mortality rates between screened 
and unscreened groups over a particular time. Differences 
in absolute mortality tend to suggest a more delicate 
balance of benefits and harms than many might expect.17 
Nonetheless, the balance of benefits and harms in any type 
of screening is often contested1, and will vary depending on 
the disease, program design, protocol design, technology 
and quality assurance.4
Some cancers are more likely to be overdiagnosed 
than others.7,13 In particular, screening is more likely to 
overdiagnose cancer if it detects early-stage cancer and 
triggers cancer treatments (as opposed to screening that 
detects – and prompts removal of – changes that can later 
become cancer, e.g. cervical and colorectal screening). To 
quote Esserman et al.:18
Physicians, patients, and the general public must 
recognize that overdiagnosis is common and 
occurs more frequently with cancer screening. 
Overdiagnosis, or identification of indolent 
cancer, is common in breast, lung, prostate, and 
thyroid cancer. Whenever screening is used, the 
fraction of tumours in this category increases. By 
acknowledging this consequence of screening, 
approaches that mitigate the problem can be tested.
Figure 2. Cancer heterogeneity and multiple screenings drive overdiagnosis
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Consistent with this, those cancers most likely to be 
overdiagnosed are prostate cancer, from prostate-specific 
antigen testing of asymptomatic men in primary care; 
breast cancer, from organised mammography screening; 
thyroid cancer, from ultrasound of the thyroid and/or 
adjoining structures; and lung cancer, from screening 
smokers using computed tomography.7,10,13,19-21 
Discussing overdiagnosis is good 
science, not an accusation of 
malpractice 
It is the nature of science to change: a scientific attitude 
entails scepticism and openness to questioning. 
Overdiagnosis in cancer screening has become topical 
because, within the science of cancer, it has become 
increasingly clear that some cancers do not need to be 
found, and that the benefit/harm balance of screening is 
less favourable than originally hoped. Unfortunately, at 
present, overdiagnosis debates sometimes fail to take 
a scientific approach, instead becoming polarised into 
perceived ‘pro-screening’ or ‘anti-screening’ camps, where 
defensiveness collides with zealousness.13 
In future, we believe it is critical for healthcare 
practitioners and researchers to hold open, rigorous 
scientific conversations about overdiagnosis, staying 
focused on the central fact that overdiagnosis is correct 
diagnosis. The people who may cause overdiagnosis are 
rarely maleficent or incompetent: they are, in large part, 
professionals doing their job to a high standard and in the 
way their profession has agreed it should be done, with 
a desire to prevent suffering and premature death from 
cancer. The problem is that, within the healthcare system, 
standards for practice have been set at a point that may 
produce more harm than good. This harms individuals 
while appearing to help them.13 In addition, any amount 
of overdiagnosis will increase the costs and decrease the 
cost-effectiveness of screening programs, thus leading 
to opportunity costs.22–24 System standards need to be 
constantly and collaboratively monitored to ensure that 
screening produces more good than harm.24,25 More 
research is needed to test whether treating the lowest 
risk screen-detected cancers differently will reduce harm 
(e.g. Francis et al.25, Lane et al.26).
Citizens expect their healthcare systems to help, not 
harm. Health professionals make their career choices 
because they are motivated to relieve suffering, not cause 
it. If we keep hold of these values, it should be possible 
for us to continue to have a constructive and productive 
conversation about overdiagnosis and how to minimise it in 
cancer screening programs. 
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